1 BTC
=
- USD
ADC Therapeutics SA
As of May 30, 2026 at 24:05 UTC
Chart
About ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Market Statistics
Trading Metrics
How to Buy ADCT
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ADCT
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesPomerantz LLP is investigating ADC Therapeutics for potential securities fraud following the December 3, 2025 announcement of LOTIS-7 trial data. Despite positive framing, the press release disclosed adverse events in two patients and cytokine release syndrome in 36.7% of patients, triggering a 14.13% stock price decline to $3.95 per share.
Pomerantz LLP announced investigations into potential securities fraud at Graphic Packaging Holding Company, Fermi Inc., and ADC Therapeutics SA. Graphic Packaging specifically lowered its full-year earnings guidance on December 8, 2025, citing production curtailments, resulting in an 8.66% stock price decline to $14.23 per share.
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics following the December 3, 2025 announcement of LOTIS-7 trial data. Despite positive framing, the data revealed adverse events in two patients and cytokine release syndrome in 36.7% of patients, triggering a 14.13% stock price decline to $3.95 per share.
The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.
